Vaccines

3d rendering white blood cells with red blood cells

Immune cell profiles may guide flu vaccine timing in pediatric stem cell transplant patients

A new study led by Vanderbilt University Medical Center researchers has identified key immune cell populations that predict how well pediatric hematopoietic stem cell transplant (HCT) recipients will respond to the influenza vaccine.

Bird flu vaccine more effective with potent adjuvant

The avian (bird) influenza vaccine creates a more robust immune response when paired with a potent ingredient known as an adjuvant, according to Vanderbilt research published in The Journal of Infectious Diseases.

Children’s antibodies highly potent against COVID-19: study

Reporting Nov. 6 in Cell Reports Medicine, Ivelin Georgiev, PhD, and colleagues demonstrated that antibodies isolated from children’s blood samples displayed high levels of neutralization and potency against variants of the COVID-19 virus, SARS-CoV-2, even when the children had not previously been exposed to or vaccinated against those variants.

James Crowe’s antibody research lands American Society for Microbiology Award

Vanderbilt University Medical Center’s James Crowe Jr., MD, has been named to receive the 2024 American Society for Microbiology Award for Applied and Biotechnological Research.

syringe

VIGH, partners get training grant to create vaccine-related research in Peru

In partnership with the Universidad Peruana Cayetano Heredia (UPCH) and the Instituto de Investigacion Nutricional (IIN), the Vanderbilt Institute for Global Health (VIGH) has received $1.2 million for a five-year training grant funded by the Fogarty International Center to establish the Peru-Vanderbilt Prevention through Vaccination Training program.

Research assistant Mahsa Majedi loads reagent used in DNA sample preparation in the genomics lab. She is part of a team of more than a dozen people at VUMC who are “sprinting” to develop — within 90 days — an antibody-based treatment to stop the spread of the Zika virus.

VUMC, Oxford team develops ‘blueprint’ to block lethal virus

Researchers at Vanderbilt University Medical Center and the University of Oxford have determined how a human monoclonal antibody isolated at Vanderbilt in 2021 can prevent infection by the potentially lethal Sin Nombre virus.

1 2 3 4 14
OSZAR »